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background: Prior studies (e.g., GWTG-HF, Medicare) have reported that only 30% of eligible HF patients fill a prescription for an aldosterone 
antagonist (AA) within 90 days of hospital discharge, but these studies largely excluded Veterans and did not utilize discharge lab values to assess 
eligibility for AA therapy.
methods: From the Veterans Administration (VA) External Peer Review Program, we identified a nationwide random sample of Veterans with 
preexisting HF who were discharged alive from a VA hospital with a primary diagnosis of HF and reduced LV systolic function (LVEF ≤ 40%) from 
10/02 to 07/09. AA-eligible patients were those with LVEF ≤ 40%, discharge serum creatinine ≤2.5 mg/dL for men (≤2.0 for women), serum 
potassium ≤ 5.0 mEq/L, absence of contraindications (hyperkalemia, concomitant ACE/ARB, gynecomastia), and prescribed beta blocker or ACE/
ARB at discharge. The primary outcome was proportion of AA-eligible patients who filled an AA prescription within 90 days of discharge.
results: Of the cohort of HF patients (n= 14,534), 64% (n=9,355) were eligible for AA (mean age 70 yrs). Beta-blocker and ACE/ARB use was 
> 85%. Thirty-six percent (n=3,408) of patients filled an AA prescription within 90 days of discharge. Between 10/02 and 07/09, there was a 
significant decrease in proportion of AA prescriptions fills within 90 days (41% to 31%, p<0.001 for trend) after adjustment for clustering by hospital. 
In addition, hospital-level variation (adjusted for year) was moderate with a median odds-ratio of 1.44, which indicates that a randomly selected 
patient at one hospital would have 0.44 times higher odds of receiving AA therapy than another randomly selected patient at a different hospital 
within the same fiscal year.
conclusion: After HF discharge from VA hospitals nationwide, there was significant hospital-level variation in the prescription of AA therapy among 
eligible patients. Further, the majority of eligible patients did not receive AA therapy. We found an unexpected decline in the use of AA over time 
which differs from other published reports. Future studies should try to understand the reasons for this progressive gap in guideline-concordant care.
